ClinicalTrials.gg
RecruitingNCT07289477Updated Apr 14, 2026

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

A Phase 1 interventional study of Human Dopaminergic Progenitor Cells in Multiple System Atrophy - Parkinsonian Subtype (MSA-P), sponsored by iRegene Therapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by iRegene Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Multiple System Atrophy with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Multiple System Atrophy · China.

Planned enrollment
12th of 13
9 · median 30
Started
2026
with 6 others
Phase 1
7 of 26
7 open now
Primary completion
2027-10
later than 14 of 18 live
Registered
17th of 26
by date
Lead sponsor
1 of 26
iRegene Therapeutics Co., Ltd.

Among the 26 studies in Multiple System Atrophy with a site in China, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 14 of the 18 other live ones, and was the 17th registered.

Multiple System Atrophy

207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.

Browse Multiple System Atrophy studies →

Open to participants now

18 of the 26 studies in Multiple System Atrophy with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Multiple System Atrophy with a site in China, or all of them as a file.
02

Study summary

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.

03

Conditions studied

  • Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 30 and 70 years (inclusive), regardless of gender.
  • The subject understands and agrees to comply with the study procedures and voluntarily provides written .
  • Diagnosed with confirmed, clinically established, or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria.
  • Current treatments for core MSA symptoms are inadequately controlled.
  • The duration of MSA-related motor symptoms (parkinsonism and/or cerebellar ataxia) is no more than 5 years.
  • Ability to walk without human assistance, defined as being able to take at least 10 steps; the use of assistive devices (e.g., a walker or cane) is permitted.
  • of at least 3 years.
  • The subject agrees not to participate in any other clinical studies for 24 months following the product administration.

Exclusion criteria

Exclusion Criteria:

  • Neurological diseases/disorders other than Multiple System Atrophy, such as Parkinson's disease, Dementia with Lewy Bodies, Essential Tremor, Progressive Supranuclear Palsy, Spinocerebellar Ataxia, Hereditary Spastic Paraplegia, Corticobasal Degeneration, Vascular Parkinsonism, Normal Pressure Hydrocephalus, or Drug-induced/Postencephalitic Parkinsonism.
  • Diagnosis of dementia.
  • Previous or current receipt of other disease-modifying therapies, or participation in clinical trials of other new drugs or novel therapies.
  • Use of medications within the past 3 months that may affect Parkinsonian symptoms, autonomic function, or the evaluation of safety.
  • Presence of or unstable medical or surgical conditions that may preclude the safe completion of the treatment or confound the treatment outcomes.
  • History of or undergoing treatment for recurrent stroke.
  • Screening brain MRI shows other significant pathological findings, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter of less than 1 cm do not warrant exclusion).
  • Subjects meeting any of the following criteria indicating advanced disease:

Speech impairment defined by a score of ≥3 on UMSARS Item 1. Swallowing impairment defined by a score of ≥3 on UMSARS Item 2. Walking impairment defined by a score of ≥3 on UMSARS Item 7. Occurrence of falls more than once per week, defined by a score of ≥3 on UMSARS Item 8.

  • History of current substance abuse and/or alcohol abuse (within 12 months prior to screening).
  • Known allergy to the product(s); or history of allergy to antibiotics or other drugs.
  • Positive screening results for active viral infection, including (HIV), Surface Antigen (HBsAg), Hepatitis B Core Antibodies, or Virus (HCV).
  • Severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency:

Severe hepatic insufficiency: ≥ 2.0 × (ULN) or AST ≥ 2.0 × ULN.

Severe renal insufficiency: Serum creatinine ≥ 1.5 × ULN or estimated (eGFR) \< 40 mL/min/1.73 m².

Severe cardiac insufficiency: (NYHA) Class 3 or 4.

  • History of thrombocytopenia within the past three months, other bleeding disorders, or current receipt of anticoagulant therapy (excluding aspirin at a dose ≤ 100 mg per day).
  • Pregnancy, lactation, or planning pregnancy.
  • History of Bipolar Disorder, Major Depressive Disorder, Schizophrenia, or other psychotic disorders.
  • Subjects judged by the investigator to have suicidal ideation at screening, or a suicide attempt within 6 months prior to screening.
  • for surgery (e.g., implantation of cochlear implants, pacemakers, defibrillators, history of stereotactic ablation, previous implantation of unilateral/bilateral similar products) or history of other surgeries within the past 6 months deemed by the investigator to potentially affect this trial, or other neurosurgical contraindications.
  • Clinically significant cardiac disease defined as: myocardial infarction, NYHA Class III or IV heart failure, uncontrolled coronary spasm, severe uncontrolled ventricular arrhythmia, or evidence of acute ischemia or abnormal conduction system on within 6 months prior to enrollment.
  • Diagnosis of .
  • Family history of congenital or inherited immunodeficiency disorders.
  • Considered by the investigator to have poor compliance.
  • Any other significant disease or condition that, in the investigator's judgment, may jeopardize the subject's safety or interfere with the study assessments.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    NouvNeu001

    During the enrollment phase for the low-dose cohort, 3 participants will be randomized to the experimental arm to receive a single administration of NouvNeu001 Injection.

    Biological: Human Dopaminergic Progenitor Cells

  • No intervention
    control

    During the enrollment phase for the low-dose cohort, 3 participants will be randomized to the control arm, which will not receive NouvNeu001 Injection.

Interventions

  • BiologicalHuman Dopaminergic Progenitor Cells

    Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events as Assessed by CTCAE V5.0

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: 52 weeks post-transplant

Secondary outcomes

  1. Change from baseline in the UMSARS total score (Part I + Part II) at Weeks 13, 26, and 52.

    Change from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) total score (Part I Score 0 \~ 48 + Part II Score 0 \~ 56; ) at Weeks 13, 26, and 52. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 13, 26, and 52 post-transplant

  2. Change from baseline in the UMSARS Part I score at Weeks 13, 26, and 52.

    Change from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part I score (0 \~ 48) at Weeks 13, 26, and 52. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 13, 26, and 52 post-transplant

  3. Change from baseline in the UMSARS Part II score at Weeks 13, 26, and 52.

    Change from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part II score (0 \~ 56) at Weeks 13, 26, and 52. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 13, 26, and 52 post-transplant

  4. Change from baseline in dopaminergic metabolism of the basal ganglia at Week 52, as measured by DAT PET imaging.

    Change from baseline in dopaminergic metabolism of the basal ganglia at Week 52, as measured by 18F-DOPA PET or 11C-CFT DAT PET imaging.

    Time frame: Weeks 52 post-transplant

  5. Change from baseline in the CGI-S score at Weeks 13, 26, and 52.

    Change from baseline in the Clinical Global Impression-Severity scale (CGI-S) score (1 \~ 7) at Weeks 13, 26, and 52. A higher score indicates more severe symptoms or worse health.

    Time frame: Weeks 13, 26, and 52 post-transplant

Other outcomes

  1. Pharmacodynamic Biomarkers (NfL)

    measurement of neurofilament light chain (NfL) levels in human blood samples.

    Time frame: Weeks 13, 26, and 52 post-transplant

  2. Pharmacodynamic Biomarkers (α-syn)

    measurement of alpha-synuclein (α-syn) levels in human blood samples.

    Time frame: Weeks 13, 26, and 52 post-transplant

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 25 phase 1 interventional studies under Multiple System Atrophy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 55. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 17, 2025
StartActual
Jan 5, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Jul 2031
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07289477
Lead sponsor
iRegene Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Jan 5, 2026
Primary completion
Oct 2027 (estimated)
Completion
Jul 2031 (estimated)
Last update
Apr 14, 2026

Study contacts

Meng Cai, Ph.D
Contact
caimeng@iregene.com
0086-027-59337986
Jing Zhao, PhD
Contact
zhaojing@iregene.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion